CBH to submit kallikren inhibitor to SFDA
Beijing-headquartered drugmaker China Biopharmaceuticals Holdings says that it has completed all trials of its developmental drug nafamoslate mesilate, which the Chinese State Food and Drug Administration requires. The firm said that it is preparing to submit the data to the SFDA, and added that it expects to receive an approval decision during 2007.
CBH said that drug, which is a kallikrein inhibitor, has potential in a range of indications, including: the treatment of disseminated intravascular coagulation; acute pancreatitis; and as a generalized anticoagulant in cardiac surgery.
The company also said that there are approximately 1.4 million DIC sufferers in China, who will be suitable for treatment if the drug goes on to receive regulatory approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze